Crosstalk between cholesterol metabolism and psoriatic inflammation

Luo, Lingling; Guo, Yong; Chen, Lihao; Zhu, Jing; Li, Chengrang

doi:10.3389/fimmu.2023.1124786

Cited by 13 publications

(18 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the assessment of metabolic risk may be an important component in the clinical management of inflammatory skin diseases ( 64 ). High-density lipoprotein possesses anti-inflammatory effects, while inflammation also reduces high-density lipoprotein levels ( 65 ). Correspondingly, psoriasis patients were noted to have reduced high-density lipoprotein levels than healthy controls ( 65 ).…”

Section: Discussionmentioning

confidence: 99%

“…High-density lipoprotein possesses anti-inflammatory effects, while inflammation also reduces high-density lipoprotein levels ( 65 ). Correspondingly, psoriasis patients were noted to have reduced high-density lipoprotein levels than healthy controls ( 65 ). It has been reported that cytokine expression can reduce high-density lipoprotein levels during inflammation, and the specific mechanism may be related to mediating the downregulation of peroxisome proliferator-activated receptor gamma expression ( 57 , 66 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis

Su,

Xu,

Huang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThere is no consensus on the effect of tumor necrosis factor-alpha (TNF-alpha) inhibitors on lipid profiles in patients with psoriasis. This study aimed to investigate the effects of TNF-alpha inhibitors on lipid profiles (triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein) in patients with psoriasis. MethodsWe searched PubMed, Embase, and Cochrane Library databases for articles published before October 17, 2023. Four TNF-alpha inhibitors (infliximab, etanercept, adalimumab, and certolizumab) were included in our study. (PROSPERO ID: CRD42023469703).ResultsA total of twenty trials were included. Overall results revealed that TNF-alpha inhibitors elevated high-density lipoprotein levels in patients with psoriasis (WMD = 2.31; 95% CI: 0.96, 3.67; P = 0.001), which was supported by the results of sensitivity analyses excluding the effect of lipid-lowering drugs. Subgroup analyses indicated that high-density lipoprotein levels were significantly increased in the less than or equal to 3 months group (WMD = 2.88; 95% CI: 1.37, 4.4; P < 0.001), the etanercept group (WMD = 3.4; 95% CI = 1.71, 5.09, P < 0.001), and the psoriasis group (WMD = 2.52; 95% CI = 0.57, 4.48, P = 0.011). Triglyceride levels were significantly increased in the 3 to 6-month group (WMD = 4.98; 95% CI = 1.97, 7.99, P = 0.001) and significantly decreased in the 6-month and older group (WMD = -19.84; 95% CI = -23.97, -15.7, P < 0.001). Additionally, Triglyceride levels were significantly increased in the psoriasis group (WMD = 5.22; 95% CI = 2.23, 8.21, P = 0.001). ConclusionOur results revealed that TNF-alpha inhibitors might temporarily increase high-density lipoprotein levels in patients with psoriasis. However, changes in triglycerides were not consistent among the different durations of treatment, with significant increases after 3 to 6 months of treatment. Future prospective trials with long-term follow-up contribute to confirming and extending our findings.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023469703.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis

Su,

Xu,

Huang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Therefore, it is of great value and clinical signi cance to elaborate the function of lipid metabolism in TA patients. Chronic in ammation increases the production of various cytokines, including TNF, IL-1, and IL-6, which have been shown to alter lipid metabolism and cause various changes in lipid and lipoprotein metabolism (19,20). The histological feature of Takayasu arteritis is "panarteritis", meaning the involvement of all layers of the arterial wall.…”

Section: Discussionmentioning

confidence: 99%

Dysregulated serum lipid profile and atherosclerosis in untreated female TA patients: a PSM analysis

Zang

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective Recent studies indicate that dyslipidemia could be a critical risk factor for cardiovascular disease in Takayasu arteritis (TA), but the relationship between dyslipidemia and the disease activity of TA itself is unclear. Methods To better understand the connection between serum lipid profiles and disease activity in TA patients, this study assessed the presence of dyslipidemia and atherosclerosis in untreated female patients. Fifty untreated female patients with Takayasu arteritis (median age 30 years) and 98 age- and BMI-matched healthy controls were enrolled. The lipid profile (TC, TG, HDL-C, LDL-C, ApoA1, ApoB, ApoE, LPa), inflammatory markers (CRP, ESR) and carotid atherosclerotic plaque frequency were evaluated. Results The levels of TG, nonHDL-C/HDL-C in TA patients were significantly higher than those in the control group, while the levels of TC, HDL-c, and ApoA1 were significantly lower than those in the control group. Spearman correlation analysis showed that CRP was positively correlated with ApoB, nonHDL-C/HDL-C, while negatively correlated with TG, HDL-c, and ApoA1. Besides, ESR was positively correlated with LDL-C, ApoB, nonHDL-C, nonHDL-C/HDL-C, but negatively correlated with ApoA1. Carotid atherosclerotic plaque was found in 8 (14.3%) patients. Multivariate regression analysis showed that the presence of atherosclerotic plaque was only related to age, but not inflammatory markers nor lipoproteins. Conclusions Overall, this study implies that untreated female TA patients have an obvious dysregulated serum lipid profile. Moreover, the disease activity of TA itself may be a risk factor for dyslipidemia, supporting the hypothesis that young TA patients may also have a higher risk of cardiovascular disease.

show abstract

“…It also serves as an immunomodulator and has been associated with Alzheimer's disease, Parkinson's disease, multiple sclerosis (MS) and psoriasis. Furthermore, both ApoE3 and ApoE4 have been associated with susceptibility to viral infections [10][11][12]. We investigated the hypothesis that ApoE might also be associated with the development of symptomatic VL in patients from an endemic region of India.…”

Section: Introductionmentioning

confidence: 99%

Apolipoprotein E Is Upregulated in Blood and Circulating Monocytes of Indian Patients With Visceral Leishmaniasis

Kausar,

Chauhan,

Roy

et al. 2024

Parasite Immunology

View full text Add to dashboard Cite

Apolipoprotein E (ApoE) has been associated with several diseases including Parkinson's disease, Alzheimer's and multiple sclerosis. ApoE also has documented immunomodulatory functions. We investigated gene expression in circulating monocytes and in bone marrows of patients with visceral leishmaniasis (VL) living in an endemic area in Bihar, India, and contrasted these with control healthy subjects or other diagnostic bone marrows from individuals in the same region. Samples from VL patients were obtained prior to initiating treatment. Our study revealed significant upregulated expression of the apoE transcript in patients with VL. Furthermore, the levels of ApoE protein were elevated in serum samples of subjects with VL compared with healthy endemic controls. These observations may provide clues regarding the complex interactions between lipid metabolism and immunoregulation of infectious and inflammatory diseases.

show abstract

Crosstalk between cholesterol metabolism and psoriatic inflammation

Cited by 13 publications

References 186 publications

Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis

Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis

Dysregulated serum lipid profile and atherosclerosis in untreated female TA patients: a PSM analysis

Apolipoprotein E Is Upregulated in Blood and Circulating Monocytes of Indian Patients With Visceral Leishmaniasis

Contact Info

Product

Resources

About